#ASH20

Paul Bröckelmann

BroeckelmannPJ

Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD 1st-line treatment in early-stage unfavorable #Hodgkin lymphoma at @ASH_hematology: https://bit.ly/2LgW0g5

Ross "FollowtheScience" Levine

rosslevinemd

#ASH20 day 1. Loved seeing everyone's tweets about the meeting today as everyone spends time supporting their colleagues, congratulating presenters, and retweeting amazing science. This is science and the hematology

Francesco Maura

FrancescoMaura4

In 2020 with @DrOlaLandgren we revealed how Melphalan has strong mutagenic activity on myeloma cells. This can understandably create fear for patients who have undergone transplant, and we have received

Elizabeth McKenna

ElizSMcKenna

In honor of the Ham-Wasserman Lecture by Andrew Roberts at #ASH20, I'd like to share some of the key #venetoclax content published in @CD_AACR over the past few years: From

David Steensma

DavidSteensma

Aspirin continues to be the most widely used anti-platelet agent, 125 years after its synthesis. But where did it come from - and why do we give it in such

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.